6
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Clinical significance of miR-138 in patients with malignant melanoma through targeting of PDK1 in the PI3K/AKT autophagy signaling pathway.

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          The present study investigated the clinical significance of miR-138 in patients with malignant melanoma (MM), which has previously been associated with tumor growth. In patients with MM, we found that the expression of miR-138 was significantly downregulated when compared with healthy control subjects. Overexpression of miR-138 in the human melanoma cell line A2058 inhibited cell proliferation and induced cell apoptosis, and increased caspase-3 and Bax protein expression when compared with a negative control group. Meanwhile, miR-138 overexpression promoted cell autophagy, induced LC3 protein expression, and suppressed the PI3K/AKT/mTOR signaling pathway and PDK1 protein expression in A2058 cells. LY294002, an inhibitor of PI3K, suppressed PI3K/AKT/mTOR signaling, induced apoptosis, inhibited cell proliferation, increased caspase-3 and Bax protein expression, and decreased PDK1 protein expression in A2058 cells following miR-138 overexpression. Collectively, our findings indicate the clinical significance of miR-138 in patients with MM through its targeting of PDK1 expression in the PI3K/AKT/mTOR autophagy signaling pathway.

          Related collections

          Author and article information

          Journal
          Oncol. Rep.
          Oncology reports
          Spandidos Publications
          1791-2431
          1021-335X
          Sep 2017
          : 38
          : 3
          Affiliations
          [1 ] Department of Dermatology, Shangqiu First People's Hospital, Henan 476100, P.R. China.
          [2 ] Research Department, Shangqiu Medical College Shangqiu, Henan 476100, P.R. China.
          [3 ] Department of Immuno-oncology, Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei 050011, P.R. China.
          Article
          10.3892/or.2017.5838
          28731179
          a29c96e9-a013-4ac2-b814-c1f337af7874
          History

          Comments

          Comment on this article